|
|
|
| The Influencing Factors of Survival Outcomes in Patients with Epithelial Ovarian Cancer After Treatment |
| ZUO Donghua, et al |
| Linyi Cancer Hospital, Shandong Linyi 276034, China |
|
|
|
|
Abstract Objective: To discuss the influencing factors of survival outcomes in patients with epithelial ovarian cancer(EOC) after initial treatment. Methods: A total of 219 patients with EOC, who were eligible for follow-up,were admitted to Linyi Tumor Hospital from Jan. 2018 to Dec. 2020 Clinical datas, such as the age, height, weight, the time of diagnosis, surgery time, surgical scope, pathological results, changes in serum carbohydrate antigen 125(CA125), the frequency and time of chemotherapy, and the time of first recurrence after initial treatment, above of the subjects were recorded. Calculate and compare the survival outcomes of these patients. Results: The average age of the 219 newly treated patients with epithelial ovarian cancer is 56.0 years (25~81 years old). The median follow-up time was 71 months (4~99 months). The FIGO stage, degree of differentiation, tumor side, underwent cytoreductive surgery or not, pelvic lymphadenectomy or not, chemotherapy frequency in initial treatment, neoadjuvant chemotherapy (NACT) frequency, ascites or not, CA125 decreased to normal within three courses of chemotherapy postoperatively or not, the recurrence interval after initial treatment was less than 12 months or not, are statistically significant factors affecting the survival outcome of EOC patients after initial treatment (P＜0.05). According to the results of multivariate COX regression analysis, FIGO stage, underwent cytoreductive surgery or not, CA125 decreased to normal within three courses of chemotherapy postoperatively or not, and whether the recurrence interval after initial treatment was ≤ 12 months, are all independent risk factors affecting the survival outcome of EOC patients after initial treatment (P＜0.05). Conclusion: Most patients with EOC are diagnosed in advanced stages, with a low 5-year survival rate. Improving diagnostic rate of early ovarian cancer, executing satisfactory cytoreductive surgery as early as possible, and postponing the recurrence time after initial treatment can improve the prognosis of patients with ovarian cancer.
|
|
|
|
|
|
[1] 沈丽娜,臧荣余.卵巢癌一级预防研究进展[J].肿瘤防治研究,2023,50(3):224-228.
[2] 王萍,陈礼梅,张丽.术前外周血单核细胞与淋巴细胞比值联合纤维蛋白原对上皮性卵巢癌患者预后的预测价值[J].中国医师进修杂志,2022,45(4):326-330.
[3] 曹冬焱.卵巢癌规范化诊疗与进展[J].中国临床医生杂志,2023,51(3):268-271.
[4] 杜彬.卵巢癌的病理分型与精准治疗[J].上海医学,2023,46(11):745-749.
[5] 郭勤浩,吴小华.2022年度卵巢癌诊治进展[J].肿瘤综合治疗电子杂志,2023,9(2):110-118.
[6] Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer[J]. Nat Rev Clin Oncol,2024,21(5):389-400.
[7] 王新娇,任芳,李彩瑜,等.血清VEGF、TAP、CA125及HE4检测在卵巢上皮性癌诊断中的临床价值[J].医药论坛杂志,2023,44(12):47-53.
[8] 韩晴,何爱琴,李咏,等.血清Stathmin、TFF3与上皮性卵巢癌患者初始肿瘤细胞减灭术治疗结局和术后复发的关系[J].国际检验医学杂志,2023,44(23):2848-2853.
[9] You B, Purdy C, Copeland LJ, et al. Identification of patients with ovarian cancer experiencing the highest benefit from bevacizumab in the first-line setting on the basis of their tumor-intrinsic chemosensitivity (KELIM): the GOG-0218 validation study[J].Clin Oncol. 2022,40(34):3965-3974.
[10] Sambasivan S. Epithelial ovarian cancer: review article[J]. Cancer Treat Res Commun,2022(33):100629. |
|
|
|
2025, Vol. 31 
